Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2005

Open Access 01-12-2005 | Debate

Assessing subgroup effects with binary data: can the use of different effect measures lead to different conclusions?

Authors: Ian R White, Diana Elbourne

Published in: BMC Medical Research Methodology | Issue 1/2005

Login to get access

Abstract

Background

In order to use the results of a randomised trial, it is necessary to understand whether the overall observed benefit or harm applies to all individuals, or whether some subgroups receive more benefit or harm than others. This decision is commonly guided by a statistical test for interaction. However, with binary outcomes, different effect measures yield different interaction tests. For example, the UK Hip trial explored the impact of ultrasound of infants with suspected hip dysplasia on the occurrence of subsequent hip treatment. Risk ratios were similar between subgroups defined by level of clinical suspicion (P = 0.14), but odds ratios and risk differences differed strongly between subgroups (P < 0.001).

Discussion

Interaction tests on different effect measures differ because they test different null hypotheses. A graphical technique demonstrates that the difference arises when the subgroup risks differ markedly. We consider that the test of interaction acts as a check on the applicability of the trial results to all included subgroups. The test of interaction should therefore be applied to the effect measure which is least likely a priori to exhibit an interaction. We give examples of how this might be done.

Summary

The choice of interaction test is especially important when the risk of a binary outcome varies widely between subgroups. The interaction test should be pre-specified and should be guided by clinical knowledge.
Appendix
Available only for authorised users
Literature
1.
go back to reference Assmann SF, Pocock SJ, Enos LE, Kasten LE: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000, 355: 1064-1069. 10.1016/S0140-6736(00)02039-0.CrossRefPubMed Assmann SF, Pocock SJ, Enos LE, Kasten LE: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000, 355: 1064-1069. 10.1016/S0140-6736(00)02039-0.CrossRefPubMed
2.
go back to reference Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association. 1991, 266: 93-98. 10.1001/jama.266.1.93.CrossRefPubMed Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association. 1991, 266: 93-98. 10.1001/jama.266.1.93.CrossRefPubMed
3.
go back to reference Walter SD: Choice of effect measure for epidemiological data. Journal of Clinical Epidemiology. 2000, 53: 931-9. 10.1016/S0895-4356(00)00210-9.CrossRefPubMed Walter SD: Choice of effect measure for epidemiological data. Journal of Clinical Epidemiology. 2000, 53: 931-9. 10.1016/S0895-4356(00)00210-9.CrossRefPubMed
6.
8.
go back to reference Furukawa T, Guyatt G, Griffith L: Can we individualize the "number needed to treat"? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology. 2002, 31: 72-76. 10.1093/ije/31.1.72.CrossRefPubMed Furukawa T, Guyatt G, Griffith L: Can we individualize the "number needed to treat"? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology. 2002, 31: 72-76. 10.1093/ije/31.1.72.CrossRefPubMed
12.
13.
go back to reference Oxman AD, Guyatt GH: A consumer's guide to subgroup analysis. Annals of Internal Medicine. 1992, 116: 78-84.CrossRefPubMed Oxman AD, Guyatt GH: A consumer's guide to subgroup analysis. Annals of Internal Medicine. 1992, 116: 78-84.CrossRefPubMed
14.
go back to reference Peto R: Statistical aspects of cancer trials. Treatment of Cancer. Edited by: Halnan KE. 1982, London:Chapman and Hall, 867-871. Peto R: Statistical aspects of cancer trials. Treatment of Cancer. Edited by: Halnan KE. 1982, London:Chapman and Hall, 867-871.
15.
go back to reference Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003, 361: 296-300. 10.1016/S0140-6736(03)12342-2.CrossRefPubMed Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003, 361: 296-300. 10.1016/S0140-6736(03)12342-2.CrossRefPubMed
16.
go back to reference Deeks JJ: Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine. 2002, 21: 1575-1600. 10.1002/sim.1188.CrossRefPubMed Deeks JJ: Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine. 2002, 21: 1575-1600. 10.1002/sim.1188.CrossRefPubMed
17.
go back to reference Elbourne D, et al: Ultrasonography in the diagnosis and management of developmental hip dysplasia (UK Hip trial). Lancet. 2002, 360: 2009-2017. 10.1016/S0140-6736(02)12024-1.CrossRefPubMed Elbourne D, et al: Ultrasonography in the diagnosis and management of developmental hip dysplasia (UK Hip trial). Lancet. 2002, 360: 2009-2017. 10.1016/S0140-6736(02)12024-1.CrossRefPubMed
18.
go back to reference Javier Jimenez F, Guallar E, Martin-Moreno JM: A graphical display useful for meta-analysis. Eur J Public Health. 1997, 7: 101-105. 10.1093/eurpub/7.1.101.CrossRef Javier Jimenez F, Guallar E, Martin-Moreno JM: A graphical display useful for meta-analysis. Eur J Public Health. 1997, 7: 101-105. 10.1093/eurpub/7.1.101.CrossRef
19.
go back to reference Mehrotra DV: Stratification issues with binary endpoints. Drug Information Journal. 2001, 35: 1343-1350.CrossRef Mehrotra DV: Stratification issues with binary endpoints. Drug Information Journal. 2001, 35: 1343-1350.CrossRef
20.
go back to reference Zhang J, Yu KF: What's the relative risk? A method of correcting the odds ratio on cohort studies of common outcomes. Journal of the American Medical Association. 1998, 280: 1690-1. 10.1001/jama.280.19.1690.CrossRefPubMed Zhang J, Yu KF: What's the relative risk? A method of correcting the odds ratio on cohort studies of common outcomes. Journal of the American Medical Association. 1998, 280: 1690-1. 10.1001/jama.280.19.1690.CrossRefPubMed
Metadata
Title
Assessing subgroup effects with binary data: can the use of different effect measures lead to different conclusions?
Authors
Ian R White
Diana Elbourne
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2005
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-5-15

Other articles of this Issue 1/2005

BMC Medical Research Methodology 1/2005 Go to the issue